Next Article in Journal
Fast Profiling of Natural Pigments in Different Spirulina (Arthrospira platensis) Dietary Supplements by DI-FT-ICR and Evaluation of their Antioxidant Potential by Pre-Column DPPH-UHPLC Assay
Previous Article in Journal
The Double Face of Mucin-Type O-Glycans in Lectin-Mediated Infection and Immunity
Previous Article in Special Issue
Effector–Immunity Pairs Provide the T6SS Nanomachine its Offensive and Defensive Capabilities
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle
Molecules 2018, 23(5), 1153; https://doi.org/10.3390/molecules23051153

Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40–CD154 Costimulatory Protein-Protein Interaction

1
Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
2
Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Carles Galdeano
Received: 6 April 2018 / Revised: 2 May 2018 / Accepted: 9 May 2018 / Published: 11 May 2018
(This article belongs to the Special Issue Protein-Protein Interactions)
View Full-Text   |   Download PDF [2202 KB, uploaded 11 May 2018]   |  

Abstract

We report the design, synthesis, and testing of novel small-molecule compounds targeting the CD40–CD154 (CD40L) costimulatory interaction for immunomodulatory purposes. This protein-protein interaction (PPI) is a TNF-superfamily (TNFSF) costimulatory interaction that is an important therapeutic target since it plays crucial roles in the activation of T cell responses, and there is resurgent interest in its modulation with several biologics in development. However, this interaction, just as all other PPIs, is difficult to target by small molecules. Following up on our previous work, we have now identified novel compounds such as DRI-C21091 or DRI-C21095 that show activity (IC50) in the high nanomolar to low micromolar range in the binding inhibition assay and more than thirty-fold selectivity versus other TNFSF PPIs including OX40–OX40L, BAFFR-BAFF, and TNF-R1-TNFα. Protein thermal shift (differential scanning fluorimetry) assays indicate CD154 and not CD40 as the binding partner. Activity has also been confirmed in cell assays and in a mouse model (alloantigen-induced T cell expansion in a draining lymph node). Our results expand the chemical space of identified small-molecule CD40–CD154 costimulatory inhibitors and provide lead structures that have the potential to be developed as orally bioavailable immunomodulatory therapeutics that are safer and less immunogenic than corresponding biologics. View Full-Text
Keywords: costimulation; drug design; immune modulation; protein-protein interaction; small molecule; TNF superfamily costimulation; drug design; immune modulation; protein-protein interaction; small molecule; TNF superfamily
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Bojadzic, D.; Chen, J.; Alcazar, O.; Buchwald, P. Design, Synthesis, and Evaluation of Novel Immunomodulatory Small Molecules Targeting the CD40–CD154 Costimulatory Protein-Protein Interaction. Molecules 2018, 23, 1153.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top